Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis
Authors' conclusion
The most effective antidiabetic agent in reducing dementia risk in T2DM is SGLT2i, followed by GLP1-RA, TZD and DPP4i, whereas insulin is associated with an elevated risk of dementia.
Study context
- Population
- Patients with T2D in trials (English or Japanese) assessing glucose-lowering drugs and dementia; PubMed, Cochrane Library, Igaku Chuo Zasshi-Web to 31 December 2023
- Participants
- 4,088,683 patients67 trials
- Comparison
- Nine antidiabetic agent classes vs reference
- Outcome
- Dementia risk
Pooled result
As reported in the abstract
- Dementia risk decreased with SGLT2i, GLP1-RA, thiazolidinediones (TZD) and DPP4i vs reference
- Insulin associated with increased dementia risk
- No significant association with metformin, sulfonylureas, glinides and α-glucosidase inhibitors
- Treatment ranking for reducing dementia risk: SGLT2i > GLP1-RA > TZD > DPP4i; insulin ranked lowest
- 63 of 67 trials were real-world database studies
Original publication
Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis. Diabetes Obes Metab. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →